BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27209485)

  • 21. Characterization of the serotonin 2A receptor selective PET tracer (R)-[
    Kramer V; Dyssegaard A; Flores J; Soza-Ried C; Rösch F; Knudsen GM; Amaral H; Herth MM
    Eur J Nucl Med Mol Imaging; 2020 Feb; 47(2):355-365. PubMed ID: 31606832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Desorption Electrospray Ionization Mass Spectrometry Imaging of Cimbi-36, a 5-HT
    Jacobsen SC; Speth NR; Xiong M; Herth MM; Kristensen JL; Palner M; Janfelt C
    Mol Imaging Biol; 2021 Oct; 23(5):676-685. PubMed ID: 33651266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging.
    Lemoine L; Becker G; Vacher B; Billard T; Lancelot S; Newman-Tancredi A; Zimmer L
    J Nucl Med; 2012 Jun; 53(6):969-76. PubMed ID: 22577236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain.
    Yang KC; Stepanov V; Martinsson S; Ettrup A; Takano A; Knudsen GM; Halldin C; Farde L; Finnema SJ
    Int J Neuropsychopharmacol; 2017 Sep; 20(9):683-691. PubMed ID: 28911007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct comparison of [(18) F]MH.MZ and [(18) F] altanserin for 5-HT2A receptor imaging with PET.
    Hansen HD; Ettrup A; Herth MM; Dyssegaard A; Ratner C; Gillings N; Knudsen GM
    Synapse; 2013 Jun; 67(6):328-37. PubMed ID: 23390031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of 4 radiolabeled antagonists for serotonin 5-HT(7) receptor neuroimaging: toward the first PET radiotracer.
    Lemoine L; Andries J; Le Bars D; Billard T; Zimmer L
    J Nucl Med; 2011 Nov; 52(11):1811-8. PubMed ID: 21990574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo PET Imaging of [11C]CIMBI-5, a 5-HT2AR Agonist Radiotracer in Nonhuman Primates.
    Prabhakaran J; DeLorenzo C; Zanderigo F; Knudsen GM; Gilling N; Pratap M; Jorgensen MJ; Daunais J; Kaplan JR; Parsey RV; Mann JJ; Kumar D
    J Pharm Pharm Sci; 2019; 22(1):352-364. PubMed ID: 31356761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and evaluation of [¹¹C]Cimbi-806 as a potential PET ligand for 5-HT₇ receptor imaging.
    Herth MM; Hansen HD; Ettrup A; Dyssegaard A; Lehel S; Kristensen J; Knudsen GM
    Bioorg Med Chem; 2012 Jul; 20(14):4574-81. PubMed ID: 22682922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognition-induced modulation of serotonin in the orbitofrontal cortex: a controlled cross-over PET study of a delayed match-to-sample task using the 5-HT2a receptor antagonist [18F]altanserin.
    Hautzel H; Müller HW; Herzog H; Grandt R
    Neuroimage; 2011 Oct; 58(3):905-11. PubMed ID: 21722741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands.
    Juncosa JI; Hansen M; Bonner LA; Cueva JP; Maglathlin R; McCorvy JD; Marona-Lewicka D; Lill MA; Nichols DE
    ACS Chem Neurosci; 2013 Jan; 4(1):96-109. PubMed ID: 23336049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding.
    Madsen MK; Fisher PM; Stenbæk DS; Kristiansen S; Burmester D; Lehel S; Páleníček T; Kuchař M; Svarer C; Ozenne B; Knudsen GM
    Eur Neuropsychopharmacol; 2020 Apr; 33():71-80. PubMed ID: 32146028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT2A antagonists for molecular imaging.
    Debus F; Herth MM; Piel M; Buchholz HG; Bausbacher N; Kramer V; Lüddens H; Rösch F
    Nucl Med Biol; 2010 May; 37(4):487-95. PubMed ID: 20447561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Classics in Neuroimaging: The Serotonergic 2A Receptor System-from Discovery to Modern Molecular Imaging.
    T L'Estrade E; Hansen HD; Erlandsson M; Ohlsson TG; Knudsen GM; Herth MM
    ACS Chem Neurosci; 2018 Jun; 9(6):1226-1229. PubMed ID: 29763291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of two fluoro-analogues of N,N-dimethyl-2-(2'-amino-4'-hydroxymethyl-phenylthio)benzylamine as serotonin transporter imaging agents using microPET.
    Jarkas N; Voll RJ; Williams L; Goodman MM
    Nucl Med Biol; 2010 Jul; 37(5):593-603. PubMed ID: 20610164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [¹⁸F]Altanserin and small animal PET: impact of multidrug efflux transporters on ligand brain uptake and subsequent quantification of 5-HT₂A receptor densities in the rat brain.
    Kroll T; Elmenhorst D; Matusch A; Celik AA; Wedekind F; Weisshaupt A; Beer S; Bauer A
    Nucl Med Biol; 2014 Jan; 41(1):1-9. PubMed ID: 24120220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro and In Vivo Characterization of Selected Fluorine-18 Labeled Radioligands for PET Imaging of the Dopamine D3 Receptor.
    Nebel N; Maschauer S; Kuwert T; Hocke C; Prante O
    Molecules; 2016 Aug; 21(9):. PubMed ID: 27589704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concise and Scalable Radiosynthesis of (+)-[
    Chavan LN; Voll R; Sanchez MM; Nye JA; Goodman MM
    ACS Chem Neurosci; 2023 Oct; 14(19):3694-3703. PubMed ID: 37748194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rational Design, Pharmacomodulation, and Synthesis of Dual 5-Hydroxytryptamine 7 (5-HT7)/5-Hydroxytryptamine 2A (5-HT2A) Receptor Antagonists and Evaluation by [(18)F]-PET Imaging in a Primate Brain.
    Deau E; Robin E; Voinea R; Percina N; Satała G; Finaru AL; Chartier A; Tamagnan G; Alagille D; Bojarski AJ; Morisset-Lopez S; Suzenet F; Guillaumet G
    J Med Chem; 2015 Oct; 58(20):8066-96. PubMed ID: 26348247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measuring endogenous changes in serotonergic neurotransmission with [
    da Cunha-Bang S; Ettrup A; Mc Mahon B; Skibsted AP; Schain M; Lehel S; Dyssegaard A; Jørgensen LM; Møller K; Gillings N; Svarer C; Knudsen GM
    Transl Psychiatry; 2019 Apr; 9(1):134. PubMed ID: 30975977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
    Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
    Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.